Double Bond Pharmaceutical is seeking a patent for the use of iron succinate
Double Bond Pharmaceutical has filed a Swedish patent application to protect the use of iron succinate for certain indications. Earlier this year, a clinical study, a collaboration between Double Bond Pharmaceutical AB and Skellefteå University, showed that Inofer (iron succinate) significantly improves iron uptake, iron saturation and iron stores in patients with heart failure and iron deficiency. DBP’s subsidiary Drugsson AB, has the distribution right for Inofer (iron succinate) in Sweden, Norway, Denmark and Finland. "We are very pleased that the Inofer study, according to the